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Morphea, also known as localized scleroderma, is
an uncommon fibrosing condition of the skin and
underlying tissue. Although the etiology is un-
known, morphea is considered an autoimmune
condition in which genetic and environmental fac-
tors contribute to disease onset.1 Although most
cases are spontaneous, several inciting factors are
associated with morphea, including trauma, surgery,
radiotherapy, and infections.2,3 Morphea has also
apparently been triggered by injections such as
vaccination, vitamin B12, and vitamin K.3 However,
morphea after interferon-b1b (IFN-b1b) injection is
rarely reported. Injection site reactions (ISR) to IFN-
b1b range from mild erythema to ulceration,4 and a
case of deep morphea after IFN-b1b injection is
described here.CASE REPORT
A 60-year-old white man with multiple sclerosis
(MS) was receiving IFN-b1b (Betaseron) injections,
0.25 mg every 2 days subcutaneously for 5 years. He
rotated injection sites from the thighs to the abdomen
and frequently reported mild ISRs that were self-
limiting. However, in March 2014 he noted severe
redness, swelling, and pain on the right inner thigh at
an injection site. He was otherwise well and afebrile
but his condition was assessed in the hospital as
possible cellulitis and he was started on intravenous
antibiotics. Deep vein thrombosis was excluded by
Doppler ultrasound studies. He had no prior history
of connective tissue disease or Raynaud’s phenom-
enon, and his other medication included aspirin,
bupropion, and venlafaxine. He stopped receiving
IFN-b1b injections on the right thigh, but the lesion
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referred to the dermatology department to rule out a
noninfectious etiology.
Examination found a well-looking man with
Fitzpatrick type II skin. The entire right lower limb
was edematous, with a tender demarcated area of
intense erythema, induration, and peau d’orange on
the medial thigh (Fig 1, A). Panniculitis was sus-
pected, and the lesion was biopsied with a deep
ellipse. Histopathology results showed a normal
epidermis with increased collagen bundles in the
dermis extending to the subcutis and a squared-off
appearance to the dermal-subcutis junction. There
was decreased adipose tissue surrounding adnexal
structures. In a perivascular and periadnexal loca-
tion, there was a lymphocytic infiltrate containing
occasional eosinophils and rare plasma cells (Fig 2).
Complete blood count showed a mild peripheral
eosinophilia, and the antinuclear antibody screen
result was negative. The final clinical diagnosis was,
therefore, deep morphea (morphea profunda sub-
type), and it was postulated that the IFN-b1b injec-
tion could have played a role.
Because of the severity of the symptoms, the
patient was treated with oral prednisone, 20 mg/d,
together with methotrexate, 10 mg/wk. IFN-b1b
injections were discontinued, and his MS remained
stable. There was a slow improvement in the lesion
on the right thigh. One month later, a similarJAAD Case Reports 2016;2:236-8.
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Fig 1. A, Morphea profunda: an erythematous, ill-defined plaque at the site of IFN-b1b
injection on the right anterior thigh. Biopsy site shown. B, Follow-up: decreased erythema and
induration of plaques on both thighs after treatment with prednisone and methotrexate for
8 months. The small superficial scar on the right thigh was from the biopsy, and the scar on the
left thigh was from incision and drainage.
Fig 2. Normal epidermis with dermal sclerosis extending
to subcutis. Perivascular and periadnexal lymphocytic
infiltrate with eosinophils. Reduced periadnexal fat. (He-
matoxylin-eosin stain; original magnification: 340.)
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of former injections, which formed an abscess
requiring incision and drainage. Culture found
Staphylococcus aureus, and he was treated with
oral cephalexin for 10 days. When the infection
resolved, the dose of prednisone was increased to
50 mg/d, and the methotrexate dose was increased
to 15 mg/wk. Over the next 6 months, there was
gradual improvement in both thigh lesions, and the
treatment was tapered. He did not have similar
indurated lesions on the abdomen. At follow-up
8 months after his initial visit, there was a near-complete remission with superficial sclerosis and
mild lipoatrophy on the left thigh and a small
superficial scar on the right thigh (Fig 1, B).DISCUSSION
Morphea, also known as localized scleroderma, is
a fibrosing disorder of the skin and subcutaneous
tissue.2 It is distinguished from systemic scleroderma
by the lack of internal organ involvement. Morphea
can be classified into plaque, linear, generalized,
bullous, and deep subtypes based on clinical fea-
tures.5 Deep morphea encompasses morphea pro-
funda, subcutaneous morphea, and disabling
pansclerotic morphea. Eosinophilic fasciitis has
also been considered a variant of deep morphea.5
The underlying etiology of morphea remains elusive.
The condition is associated with autoimmune thy-
roid disease as well as alopecia areata, vitiligo, lichen
planus, and type I diabetes.1,3
The following diagnostic criteria have been pro-
posed for morphea profunda: (1) clinical—diffuse,
taut, bound-down, deep sclerosis of the skin; (2)
histopathologic—appreciable hyalinization and
thickening of collagen bundles of both the pannicu-
lus and the fascia with a dense inflammatory cell
infiltrate; (3) therapeutic—response to antimalarial
agents, systemic corticosteroids, or other anti-
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morphea can show peripheral eosinophilia.5
Several triggers for morphea have been reported,
including surgery, penetrating trauma, injection,
zoster, radiation therapy, diagnostic x-ray, and
extreme exercise.2,3,6 A recent study highlighted
the role of skin trauma in morphea in both adults
and children.6 In terms of injections, rare cases of
morphea after vitamin B12 and vitamin K injections
and vaccinations have been reported.3 One case of a
morpheaform reaction to IFN-b1b injection on the
thighs and abdomen was reported in 2013, and this
patient, as in this reported patient, was also using the
agent for a long time before the onset of symptoms.7
A case of morphea on the anterior thighs 6 months
after injection of IFN- b1a was recently reported;
lesions appear to be similar to this case.8 Whether the
sclerosing reaction in these cases is caused by
physical trauma from repeated injection or by a
profibrotic effect from interferon itself remains
controversial. Cytokine dysregulation has been
implicated in the pathogenesis of systemic sclerosis,
with tumor necrosis factor, T helper 2 cells, and
interleukin-4 playing a role in activating fibro-
blasts9,10; a similar mechanism may be at play in
certain cases of morphea.
Interferon beta is an effective therapy for
relapsing-remitting MS, but one of the common
side effects is ISR, which occurs in up to 85% of
patients. These reactions vary widely from mild
erythema and edema to indurated plaques and
ulcers.4 Areas with less subcutaneous fat, such as
the thighs, are more frequently affected by ISR. Cases
of lupus panniculitis, and lobular panniculitis, have
been described.11,12
Treatment of morphea can be challenging, but
many cases involute spontaneously and mild cases
can be followed. There can, however, be severe
atrophy or scarring as possible sequelae.
Widespread, linear, or deep morphea is increasingly
managed with systemic agents like prednisone ormethotrexate, and phototherapy with ultraviolet A1
has also been used effectively.2
This case illustrates the potential for severe ISR
from IFN-b1b and also emphasizes the role of trauma
or cytokine dysregulation in the pathogenesis of
morphea and the utility of immunosuppressive
therapy for deep morphea.
The authors thank Dr. Yasmine Ayroud for providing
the histology slides.
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